28 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ivosidenib with azacitidine in the NHS in England.

For the time being, the combination of ivosidenib and azacitidine is not recommended for the treatment of adults with newly diagnosed acute myeloid leukaemia with an IDH1 R132 mutation who cannot have standard intensive induction chemotherapy.

Read NICE draft guidance consultation